# EDGAR Filing Document

**Accession Number:** 0001954488
**File Stem:** 0001213900-25-053888
**Filing Date:** 2025-6
**Character Count:** 4463
**Document Hash:** 3e39342eee3f88c851b01598966599df
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-053888.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001213900-25-053888

**CONFORMED SUBMISSION TYPE**: 8-A12B

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jyong Biotech Ltd.
- **CENTRAL INDEX KEY:** 0001954488
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 8-A12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42701
- **FILM NUMBER:** 251043685

**BUSINESS ADDRESS:**
- **STREET 1:** 23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
- **STREET 2:** XIZHI DIST.
- **CITY:** NEW TAIPEI CITY
- **STATE:** F5
- **ZIP:** 221
- **BUSINESS PHONE:** (8862) 27325205

**MAIL ADDRESS:**
- **STREET 1:** 23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
- **STREET 2:** XIZHI DIST.
- **CITY:** NEW TAIPEI CITY
- **STATE:** F5
- **ZIP:** 221

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES**

**PURSUANT TO SECTION 12(b) OR (g) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**Jyong Biotech Ltd.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Cayman Islands** | **Not Applicable** |
| (State or other jurisdiction<br> of incorporation) | (IRS Employer<br> Identification Number) |

---

**23F-3, No. 95, Section 1, Xintai 5<sup>th</sup> Road,<br> Xizhi District, New Taipei City,<br> Taiwan, 221**

(Address of principal executive offices and zip code)

**Securities to be registered pursuant to Section 12(b) of the Exchange Act:**

---

| | |
|:---|:---|
| **Title of each class <br> to be registered** | **Name of each exchange on which <br> each class is to be registered** |
| Ordinary Shares, par value US$0.00001 per share | The Nasdaq Stock Market LLC |

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ☐

Securities Act registration statement file number to which this form relates: **333-277725**

Securities to be registered pursuant to Section 12(g) of the Act: **None**

**Item 1. Description of Registrant's Securities to be Registered.**

**Ordinary shares**

The securities to be registered hereby are the ordinary shares, par value US$0.00001 per share, of Jyong Biotech Ltd., a Cayman Islands exempted company (the "**Registrant**"). The description of the Registrant's ordinary shares is contained in the section entitled "Description of Share Capital" to the Registrant's Registration Statement on [Form F-1](https://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696-02.htm) (File No. 333-277725), as originally filed with the Securities and Exchange Commission (the "**Commission**") on March 7, 2024, and thereafter amended from time to time (the "**Registration Statement**"), is hereby incorporated herein by reference. Any prospectus that constitutes part of the Registration Statement and that is subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, shall also be deemed to be herein incorporated by reference.

**Item 2. Exhibits**

Pursuant to the "Instructions as to Exhibits" section of Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Jyong Biotech Ltd.** | **Jyong Biotech Ltd.** | **Jyong Biotech Ltd.** |
| Dated: June 12, 2025 | By: | */s/ Fu-Feng Kuo* | */s/ Fu-Feng Kuo* |
|  |  | Name: | Fu-Feng Kuo |
|  |  | Title: | Chief Executive Officer |

---